Repare Therapeutics Statistics
Total Valuation
RPTX has a market cap or net worth of $139.22 million. The enterprise value is -$95.00 million.
| Market Cap | 139.22M |
| Enterprise Value | -95.00M |
Important Dates
The last earnings date was Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RPTX has 42.45 million shares outstanding. The number of shares has increased by 4.72% in one year.
| Shares Outstanding | 42.45M |
| Shares Change (YoY) | +4.72% |
| Shares Change (QoQ) | +4.47% |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 93.64% |
| Float | 15.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.42 |
| Forward PS | 2.53 |
| PB Ratio | 0.60 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.33, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.33 |
| Quick Ratio | 7.86 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.80% and return on invested capital (ROIC) is -30.13%.
| Return on Equity (ROE) | -19.80% |
| Return on Assets (ROA) | -16.50% |
| Return on Capital (ROIC) | -30.13% |
| Revenue Per Employee | $546,698 |
| Profits Per Employee | -$255,268 |
| Employee Count | 179 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -12.37M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.52% in the last 52 weeks. The beta is 0.56, so RPTX's price volatility has been lower than the market average.
| Beta (1Y) | 0.56 |
| 52-Week Price Change | -68.52% |
| 50-Day Moving Average | 4.51 |
| 200-Day Moving Average | 6.69 |
| Relative Strength Index (RSI) | 36.32 |
| Average Volume (30 Days) | 126,831 |
Short Selling Information
The latest short interest is 608,257, so 1.43% of the outstanding shares have been sold short.
| Short Interest | 608,257 |
| Short Previous Month | 681,023 |
| Short % of Shares Out | 1.43% |
| Short % of Float | 4.03% |
| Short Ratio (days to cover) | 5.80 |
Income Statement
In the last 12 months, RPTX had revenue of $97.86 million and -$45.69 million in losses. Loss per share was -$1.10.
| Revenue | 97.86M |
| Gross Profit | 97.86M |
| Operating Income | -70.73M |
| Pretax Income | -58.06M |
| Net Income | -45.69M |
| EBITDA | -53.84M |
| EBIT | -58.06M |
| Loss Per Share | -$1.10 |
Balance Sheet
The company has $237.00 million in cash and $2.78 million in debt, giving a net cash position of $234.22 million or $5.52 per share.
| Cash & Cash Equivalents | 237.00M |
| Total Debt | 2.78M |
| Net Cash | 234.22M |
| Net Cash Per Share | $5.52 |
| Equity / Book Value | 231.95M |
| Book Value Per Share | 5.46 |
| Working Capital | 224.10M |
Cash Flow
In the last 12 months, operating cash flow was -$83.44 million and capital expenditures -$1.46 million, giving a free cash flow of -$84.90 million.
| Operating Cash Flow | -83.44M |
| Capital Expenditures | -1.46M |
| Free Cash Flow | -84.90M |
| FCF Per Share | -$2.01 |
Margins
Gross margin is 100.00%, with operating and profit margins of -72.27% and -46.69%.
| Gross Margin | 100.00% |
| Operating Margin | -72.27% |
| Pretax Margin | -59.33% |
| Profit Margin | -46.69% |
| EBITDA Margin | -55.01% |
| EBIT Margin | -59.33% |
| FCF Margin | -86.76% |
Dividends & Yields
RPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.72% |
| Shareholder Yield | -4.72% |
| Earnings Yield | -32.82% |
| FCF Yield | -60.98% |
Analyst Forecast
The average price target for RPTX is $17.33, which is 428.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.33 |
| Price Target Difference | 428.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 12.03% |
| EPS Growth Forecast (5Y) | -18.43% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RPTX has an Altman Z-Score of 1.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 2 |